Financial Performance - The company's operating revenue for Q1 2022 was CNY 10.38 billion, representing a year-on-year increase of 28.87%[3] - Net profit attributable to shareholders of the listed company was CNY 462.51 million, a decrease of 45.41% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 800.95 million, an increase of 21.73% year-on-year[3] - Basic earnings per share were CNY 0.18, down 45.45% from the previous year[3] - The company reported a significant contribution to revenue growth from products such as mRNA COVID-19 vaccines and other pharmaceutical products[5] - The decline in net profit was attributed to a decrease in non-recurring gains, which fell by CNY 527 million year-on-year[5] - The total comprehensive income attributable to the parent company in Q1 2022 was RMB 275,402,324.32, compared to RMB 925,638,004.58 in Q1 2021, representing a decrease of approximately 70.3%[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 95.77 billion, an increase of 2.66% from the end of the previous year[3] - The equity attributable to shareholders of the listed company was CNY 38.33 billion, a decrease of 2.20% compared to the end of the previous year[3] - Total liabilities as of March 31, 2022, amounted to RMB 95,774,597,184.39, an increase from RMB 93,293,790,957.96 as of December 31, 2021[16] - Current liabilities totaled RMB 30,305,396,039.15 as of March 31, 2022, compared to RMB 29,309,945,287.65 at the end of 2021, indicating a growth of 3.4%[16] - Long-term borrowings increased to RMB 7,954,651,573.23 as of March 31, 2022, up from RMB 6,694,183,385.90 at the end of 2021, representing a rise of 18.8%[16] Cash Flow - The net cash flow from operating activities was CNY 865.59 million, reflecting a year-on-year increase of 17.49%[3] - In Q1 2022, the company reported a net cash flow from operating activities of RMB 865,594,441.10, an increase from RMB 736,760,723.49 in Q1 2021, representing a growth of approximately 17.5%[21] - The company recorded a net cash outflow from investing activities of RMB 1,469,727,633.77 in Q1 2022, compared to a net outflow of RMB 1,574,695,133.74 in Q1 2021, showing a decrease in cash outflow by approximately 6.7%[22] - The company’s net cash flow from financing activities in Q1 2022 was RMB 1,543,569,247.09, an increase from RMB 1,202,916,178.59 in Q1 2021, reflecting a growth of approximately 28.4%[22] Research and Development - Research and development expenses for Q1 2022 were RMB 805,341,078.97, compared to RMB 640,838,020.18 in Q1 2021, marking an increase of 25.7%[18] - The company’s innovative product development and commercialization efforts are ongoing, with the approval of Hanshuan (Surulitin) for clinical use in March 2022[10] - The CAR-T cell therapy product FKC 889 received approval for clinical trials in China for adult patients with relapsed or refractory mantle cell lymphoma[11] Market and Product Development - The company continued to supply the Comirnaty (mRNA COVID-19 vaccine) to Hong Kong, Macau, and Taiwan, with over 24 million doses administered by the end of March 2022[9] - The company received permission from the Medicines Patent Pool to produce and supply generic versions of Merck's and Pfizer's COVID-19 oral medications to low- and middle-income countries[9] - The company is actively advancing the development of innovative products and technologies while deepening its presence in overseas markets[9] Shareholder Information - The top shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 938,095,290 shares, accounting for 36.60% of total shares[6] - HKSCC Nominees Limited holds 551,359,832 shares, representing 21.51% of total shares[6] Financing Activities - The company completed the issuance of a medium-term note totaling RMB 500 million with an interest rate of 3.50% in March 2022[13] - The company issued a short-term financing bond totaling RMB 600 million with an interest rate of 2.65% in April 2022[13]
复星医药(02196) - 2022 Q1 - 季度财报